Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients

Background: To date, no biomarkers are effective in predicting the risk of developing immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). This study aims to evaluate the association between basal absolute eosinophil count (AEC) and irAEs during treatme...

Full description

Bibliographic Details
Main Authors: Elisa Giommoni, Roberta Giorgione, Agnese Paderi, Elisa Pellegrini, Elisabetta Gambale, Andrea Marini, Andrea Antonuzzo, Riccardo Marconcini, Giandomenico Roviello, Marco Matucci-Cerinic, David Capaccioli, Serena Pillozzi, Lorenzo Antonuzzo
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Immuno
Subjects:
immune checkpoint inhibitors
immunotherapy
immune-related adverse events
solid tumors
absolute eosinophil count
biomarker
Online Access:https://www.mdpi.com/2673-5601/1/3/17

Internet

https://www.mdpi.com/2673-5601/1/3/17

Similar Items